Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for NSTM.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 0.00
March 31, 2026 0.2282M
December 31, 2025 0.0259M
September 30, 2025 0.0305M
June 30, 2025 0.0645M
March 31, 2025 0.041M
December 31, 2024 0.00
September 30, 2024 0.10M
June 30, 2024 0.10M
March 31, 2024 0.275M
December 31, 2023 0.375M
September 30, 2023 0.045M
June 30, 2023 0.163M
March 31, 2023 0.062M
December 31, 2022 0.115M
September 30, 2022
June 30, 2022
March 31, 2022
December 31, 2021
September 30, 2021
June 30, 2021
March 31, 2021
December 31, 2020
September 30, 2020
June 30, 2020
Date Value
March 31, 2020
December 31, 2019
September 30, 2019
June 30, 2019
March 31, 2019
December 31, 2018
September 30, 2018
June 30, 2018
March 31, 2018
December 31, 2017
September 30, 2017
June 30, 2017
March 31, 2017
December 31, 2016
September 30, 2016
June 30, 2016
March 31, 2016
December 31, 2015
September 30, 2015
June 30, 2015
March 31, 2015
December 31, 2014
September 30, 2014
June 30, 2014
March 31, 2014

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Brainstorm Cell Therapeutics, Inc. 0.898M
Summit Therapeutics, Inc. 230.57M
Kezar Life Sciences, Inc. 0.267M
Protara Therapeutics, Inc. -0.026M
Clene, Inc. 6.313M